216 related articles for article (PubMed ID: 37866368)
1. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.
Hilmi M; Delaye M; Muzzolini M; Nicolle R; Cros J; Hammel P; Cardot-Ruffino V; Neuzillet C
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1129-1142. PubMed ID: 37866368
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
3. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
5. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
6. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.
Heumann T; Azad N
Cancer Metastasis Rev; 2021 Sep; 40(3):837-862. PubMed ID: 34591243
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
8. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
9. Uncovering key targets of success for immunotherapy in pancreatic cancer.
Pretta A; Lai E; Persano M; Donisi C; Pinna G; Cimbro E; Parrino A; Spanu D; Mariani S; Liscia N; Dubois M; Migliari M; Impera V; Saba G; Pusceddu V; Puzzoni M; Ziranu P; Scartozzi M
Expert Opin Ther Targets; 2021 Nov; 25(11):987-1005. PubMed ID: 34806517
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
11. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
[TBL] [Abstract][Full Text] [Related]
12. Delivering a Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma.
Lavania S
Gastroenterology; 2022 Nov; 163(5):1159-1161. PubMed ID: 36067817
[No Abstract] [Full Text] [Related]
13. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy.
Luong T; Golivi Y; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2022 Dec; 68():107-115. PubMed ID: 36096869
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
15. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
[TBL] [Abstract][Full Text] [Related]
16. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
17. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel.
Brouwer TP; Vahrmeijer AL; de Miranda NFCC
Cell Oncol (Dordr); 2021 Apr; 44(2):261-278. PubMed ID: 33710604
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.
Pandey V; Storz P
Expert Rev Anticancer Ther; 2019 Jun; 19(6):473-482. PubMed ID: 31148495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
